Telomir Pharmaceuticals, Inc. Stock-Based Compensation
Telomir Pharmaceuticals, Inc. (TELO) reported Stock-Based Compensation of $238.54 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-13
- Telomir Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $198.73K, a 95.74% decline year-over-year.
- Telomir Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $39.80K, a 97.11% decline year-over-year.
- Telomir Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was -$7.95K, a 100.39% decline year-over-year.
- Telomir Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was -$741.86K.
- Telomir Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $5.29M, a 22.96% decline from fiscal 2024.
- Telomir Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $6.87M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $198.73K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $238.54K 10-Q · filed 2026-08-13 | $230.59K derived: sum of 3 quarters · filed 2026-08-13 | -$511.27K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $39.80K 10-Q · filed 2026-05-14 | $31.85K derived: sum of 2 quarters · filed 2026-05-14 | -$710.00K derived: sum of 3 quarters · filed 2026-05-14 | $3.95M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$7.95K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$749.81K derived: sum of 2 quarters · filed 2026-03-17 | $3.91M derived: sum of 3 quarters · filed 2026-08-13 | $5.29M 10-K · filed 2026-03-17 |
| 2025-09-30 | -$741.86K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $3.92M derived: sum of 2 quarters · filed 2026-08-13 | $5.30M 10-Q · filed 2025-11-10 | $7.36M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $4.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $6.04M 10-Q · filed 2026-08-13 | $8.10M derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-03-31 | $1.38M 10-Q · filed 2026-05-14 | $3.44M derived: sum of 2 quarters · filed 2026-05-14 | ||
| 2024-12-31 | $2.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $6.87M 10-K · filed 2026-03-17 | ||
| 2024-09-30 | $4.81M 10-Q · filed 2025-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |